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(e.g. calpain inhibitor I) which inhibit the lysosomal
cathepsins and partially the proteasome as well or
even better than the calpains.
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Introduction
The ubiquitous calpains, µ- and m-calpain (µ- and mCP),
are cytosolic calcium-dependent cysteine proteases that
are present in almost all mammalian cells (see Sorimachi
and Suzuki, 2001, for a recent review). Usually the cal-
pains coexist with their specific endogenous protein in-
hibitor, calpastatin, which binds reversibly to the Ca2 +-
activated enzymes and inhibits them selectively and
efficiently (Takano et al., 1995).
Although results with transgenic (knockout) mice defi-
cient in calpain small subunit gene (Arthur et al., 2000)
point to essential cellular functions of the calpains, and a
great number of putative calpain substrates have been
demonstrated in vitro, not yet many calpain-dependent
processes have been definitely identified. The ubiquitous
calpains seem to be involved in signaling pathways (Sato
and Kawashima, 2001), controlling cell proliferation (Car-
ragher et al., 2002), differentiation (Yajima and Kawa-
shima, 2002) and motility (Glading et al., 2002) as well as
cell death (Squier et al., 1999; Wang, 2000; Lu et al.,
2002; Gil-Parrado et al., 2002). Proteolysis by undue ac-
tivity of ubiquitous calpains has been implicated in vari-
ous pathologies, such as neuronal and myocardial is-
chemia/reperfusion, inflammation or neurodegenerative
disorders (reviewed in Vanderklish and Bahr, 2000;
Huang and Wang, 2001). Therefore, calpains constitute
potential therapeutic targets in diseases.
A great number of conclusions concerning the role of
calpains in physiological or pathological processes is
based on the effects of calpain inhibitors in cultured cells
or animal models. Manipulation of the cellular level of cal-
pastatin by overexpression or antisense techniques have
been used in cell culture studies (e.g. Hiwasa et al., 2002),
but the large majority of experiments have been per-
formed with exogenous synthetic calpain inhibitors that
are sufficiently cell-permeable to reach their intracellular
targets.
The search for cell-permeable calpain inhibitors has
been an ongoing process following the discovery of the
enzyme over 30 years ago (Donkor, 2000). Nonselective
calpain inhibitors such as EDTA and EGTA (Ca2 +-chela-
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The ubiquitous calpains, µ- and m-calpain, have been
implicated in essential physiological processes and
various pathologies. Cell-permeable specific in-
hibitors are important tools to elucidate the roles of
calpains in cultivated cells and animal models. The
synthetic N-acetylated 27-mer peptide derived from
exon B of the inhibitory domain 1 of human calpas-
tatin (CP1B) is unique as a potent and highly selective
reversible calpain inhibitor, but is poorly cell-perme-
ant. By addition of N-terminal cysteine residues we
have generated a disulfide-conjugated CP1B with the
cell-penetrating 16-mer peptide penetratin derived
from the third helix of the Antennapedia homeo-
domain protein. The inhibitory potency and selectivi-
ty of CP1B for calpain versus cathepsin B and L, cas-
pase 3 and the proteasome was not affected by the
conjugation with penetratin. The conjugate was
shown to efficiently penetrate into living LCLC 103H
cells, since it prevents ionomycin-induced calpain
activation at 200-fold lower concentration than the
non-conjugated inhibitor and is able to reduce cal-
pain-triggered apoptosis of these cells. Penetratin-
conjugated CP1B seems to be a promising alternative
to the widely used cell-permeable peptide aldehydes
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tors) were followed by more potent and/or more selective
calpain inhibitors isolated from natural sources or synthe-
sized (reviewed in Wang and Yuen, 1997; Donkor, 2000).
Most of them react covalently with the catalytic cysteine
residue of calpain, but, with few exceptions, their selec-
tivity for the calpains is low. For instance, various peptide
aldehydes that have been extensively used for in vivo cal-
pain inhibition (e.g. Ac-Leu-Leu-Nle-CHO, here abbrevi-
ated as AcLLNal, ‘calpain inhibitor I’), are potent in-
hibitors also of the lysosomal cathepsins L and B (Sasaki
et al., 1990) and of the proteasome (Stein, et al., 1996).
Moreover, the calpain inhibitor calpeptin (Z-Leu-Nle-
CHO) was shown to inhibit protein tyrosine phos-
phatases as well (Schoenwaelder and Burridge, 1999).
During the last decade much effort has been spent in the
development of peptidic, peptidomimetic or non-peptide
calpain inhibitors of improved selectivity and good
bioavailability, but few of these inhibitors have been com-
pletely characterized in terms of selectivity or have been
used extensively as tools in basic research (Donkor,
2000; Hernandez and Roush, 2002).
The α-mercaptoacrylic acid derivative PD150606, a
non-peptide cell-permeable calpain inhibitor that binds
to the calmodulin-like domains of the large and the small
subunit and inhibits calpain uncompetitively, has been
considered to be selective for calpain (Wang et al., 1996),
but has recently been shown to interfere with excitoxici-
ty-dependent motor neuron death purely mediated
through Ca2 +-permeable AMPA receptors despite other
calmodulin and calpain inhibitors were not effective (Van
Den Bosch et al., 2002).
The most selective synthetic inhibitor of calpains that
is presently available is a N-acetylated and C-amidated
27-mer peptide derived from exon B of the inhibitory do-
main 1 of human calpastatin (CP1B; Maki et al., 1989)
which binds reversibly to the catalytic subunit of µ- and
m-calpain (Maki et al., 1988). This peptide, also called
‘acetyl calpastatin 27-peptide’ (AC27P; Gil-Parrado
et al., 2002), does not inhibit papain or trypsin (Maki et al.,
1989) and is considered to be highly selective for the
ubiquitous calpains, although so far quantitative data on
its inhibitory specificity have not been reported. CP1B,
which is commercially available, has successfully been
used by several investigators for inhibition of calpain ac-
tivity in living cells (Eto et al., 1995; Yamazaki et al.,
1997a,b; Kusakawa et al., 2000; Blomgren et al., 2001;
Shiraishi et al., 2001; Gil-Parrado et al., 2002). Using a
rhodamine-labeled peptide, uptake of CP1B into cells
was confirmed (Eto et al., 1995). However, high concen-
trations were needed by all investigators to achieve intra-
cellular effects, indicating that the 27-mer is poorly cell-
permeable.
Here we report quantitative in vitro inhibition data con-
firming the presumed high selectivity of CP1B for µ-cal-
pain over other typical intracellular proteases, such as
cathepsin L and B, caspase 3 and the proteasome. Cell
permeability of this highly selective calpain inhibitor was
substantially increased by conjugation with the cell-pen-
etrating peptide penetratin, a 16-mer peptide derived
from the third helix of the homeodomain of the Antenna-
pedia protein (Derossi et al., 1998) which has been wide-
ly used for intracellular delivery of peptides and oligonu-
cleotides (Fischer et al., 2001). The resulting new calpain
inhibitor, penetratin-calpastatin peptide 1B (PCP1B), was
396 S. Gil-Parrado et al.
Fig. 1 Structure and Synthesis of the Calpastatin Exon 1B-Derived Peptide-Penetratin Conjugate (PCP1B).
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able to inhibit ionomycin-induced calpain activation in liv-
ing cells at submicromolar concentrations and to prevent
calpain-triggered apoptosis. These features constitute a
promising substitute for widely used cell-permeable cal-
pain inhibitors of low selectivity. 
Results
Synthesis of Penetratin-Conjugated Calpastatin
Exon 1B-Derived Peptide (PCP1B)
The CP1B-penetratin conjugate 3 was synthesized as
shown in Figure 1. To crossbridge the calpastatin-derived
peptide with penetratin via a disulfide bridge, both pep-
tides were appropriately modified by N-terminal elonga-
tion with N-acetyl cysteine. Selective formation of the
disulfide bond was achieved by reacting S-Npys-activat-
ed peptide 1 with the free thiol of modified penetratin 2
(Bernatowicz et al., 1986). The resulting conjugate 3,
penetratin-calpastin peptide 1B (PCP1B), was fully char-
acterized by RP-HPLC, quantitative amino acid analysis,
and ESI-MS (data not shown). The solubility of CP1B was
substantially increased by the conjugation with the basic
penetratin peptide.
CP1B and PCP1B Are Potent and Selective Calpain
Inhibitors
The inhibitory profile of CP1B against four typical cellular
cysteine proteases and the human 20S proteasome
demonstrates that the calpastatin-derived peptide is a
very potent (Ki = 0.2 nM) and highly selective inhibitor of
calpain (Table 1). Whereas the activity of cathepsin B,
caspase 3 and the chymotryptic activity of the 20S pro-
teasome are virtually not affected, the selectivity for µ-
calpain over cathepsin L is still 30 000-fold. Inhibition of
cathepsin L by CP1B is comparable to that obtained with
a ‘scrambled’ peptide of the same amino acid composi-
tion (Eto et al., 1995). In contrast, the cell-permeable pep-
tidyl aldehyde Ac-LLNal (calpain inhibitor I) has about the
same affinity for cathepsin B and even 160-fold higher
affinity for cathepsin L when compared with µ-calpain
(Table 1).
The high inhibitory potency of CP1B for calpain re-
mains essentially unchanged after conjugation with pen-
etratin, whereas the N-acetylated Cys-penetratin vector
(AcP) alone does not inhibit µ-calpain. Ki values of
PCP1B for the two cathepsins are still in the micromolar
range, and a similar micromolar Ki was determined with
AcP itself. Inhibition of cathepsin L and B by AcP and
PCP1B was temporary, indicating that the free and the
conjugated penetratin peptide is slowly degraded as a
substrate. This was confirmed by the detection of cleav-
age products after incubation with higher concentrations
of cathepsin L (≥0.25 nM). PCP1B was cleaved by
cathepsin L in the penetratin portion between Gln9’ and
Asn10’, and AcP additionally between Arg11’ and Arg12’
(see sequences in Figure 1). In contrast, in PCP1B no
cleavages were observed with µ-calpain, even with 100-
fold higher enzyme concentrations than used in the inhi-
bition assays. From this we expect that the penetratin
moiety may be proteolytically degraded by intracellular
proteases after cellular uptake, as has been suggested
(Waizenegger et al., 2002). Penetratin contains several
basic residues which are preferred cleavage sites of pro-
teases, and a half life of 1 h has been estimated in mam-
malian reticulocytes (Lindgren et al., 2000a).
PCP1B Is a Cell-Permeable Calpain Inhibitor
LCLC 103H cells, a cell line derived from a human large
cell lung carcinoma (Bepler et al., 1988), were used for
cell permeation studies, because we had shown previ-
ously that ionomycin-induced calpain activity in these
cells is effectively inhibited by preincubation with AC27P
(CP1B) (Gil-Parrado et al., 2002). Here we compared the
inhibitory effect of PCP1B and CP1B on the intracellular
calpains. Ionomycin-induced hydrolysis of the cell-per-
meable fluorogenic substrate Suc-LLVY-amc was meas-
Cell-Permeable Calpastatin Peptide 397
Table 1 Selectivity of Calpain Inhibition by Calpastatin-Derived Peptide 1B (CP1B) and Its Penetratin Conjugate (PCP1B). 
Inhibitor Ki (µM)a
µ-Calpain Cathepsin L Cathepsin B Proteasomeb Caspase 3
CP1B 0.0002 6 ≥500 ≥200 ≥500
CP1B scrambledc 6 6 ≥500 ≥200 ≥200
PCP1B 0.0005 0.8e 12e ≥200 ≥200
AcPc ≥50 1.0e ≥130e ≥200 ≥200
AcLLNalc 0.003d 0.00003 0.002d 0.5e ≥9000
aMean of 5 – 10 experiments with individual inhibitor concentrations (S.D.<10%). ≥ values are 10-fold the highest used inhibitor con-
centration that resulted in less than 10% inhibition.
bChymotryptic activity of the human 20S proteasome.
cData obtained with ‘scrambled’ CP1B (see ‘Results’) and AcP (N-acetyl-Cys-penetratin) are included as controls, data with AcLLNal
(‘calpain inhibitor I’) for comparison.
dData taken from Schaschke et al. (1996).
eTemporary inhibition (see text for explanation).
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ured in non-treated control cells (100%) and after prein-
cubation with increasing concentrations of CP1B and
PCP1B, respectively (Figure 2). Whereas ionomycin-in-
duced activity was reduced to 15% by 50 µM CP1B (a
concentration widely used in the cell culture models cited
in the Introduction section), a concentration of PCP1B as
low as 0.25 µM yielded almost complete inhibition. Prein-
cubation of the cells with the penetratin vector (AcP) itself
had no significant effect (data not shown). These data
clearly demonstrate a substantial increase of cell-perme-
ability due to the conjugation of CP1B with penetratin.
The penetratin-conjugated peptide is able to penetrate
into LCLC 103H cells where it prevents ionomycin-in-
duced calpain activation at roughly 200-fold lower con-
centrations (in the surrounding medium) than the non-
conjugated inhibitor.
PCP1B Protects LCLC 103H Cells against
Ionomycin-Induced Apoptosis
We have recently shown that ionomycin-activated cal-
pain triggers apoptosis in LCLC 103H cells and that
apoptosis was prevented by preincubation of these cells
with 50 µM CP1B (AC27P; Gil-Parrado et al., 2002). Here
we used this model to compare the effects of CP1B and
PCP1B on the percentage of apoptotic cells, estimated
by FACS analysis for phosphatidyl serine externalization
(annexin V binding) and propidium iodide uptake 3 h after
incubation with 2 µM ionomycin (Figure 3). Whereas
apoptotic cells were reduced to roughly 25% by 50 µM
CP1B, the same reduction was achieved by only 10 µM
PCP1B. The penetratin vector itself had no significant ef-
fect on the number of apoptotic cells (data not shown). 
Discussion
As long as the three-dimensional structure of a calcium-
actived calpain or a substrate/inhibitor complex of cal-
pain is not available, structure-based modeling of syn-
thetic calpain inhibitors will be not feasible. It remains to
be established whether the recently published structure
of a Ca2 +-activated ‘minicalpain’ comprising the catalytic
domain II plus domain I (Moldoveanu et al., 2002) will en-
able the design of more selective inhibitors, since this
very papain-like fragment displays less than 5% of the
specific enzymatic activity of complete calpain. It seems
probable that other domains of the calpain molecule par-
ticipate in substrate recognition and are responsible for
the highly selective binding of protein substrates and of
the endogenous protein inhibitor calpastatin. This is un-
derscored by the results of structure-activity relationship
(SAR) studies (Donkor, 2000) indicating that affinity and
selectivity of calpain for small peptide substrates and in-
hibitors are low when compared to other cysteine pro-
teases.
The shortest peptide binding to calpain with outstand-
ing affinity and selectivity is the 27-mer derived from exon
1B of calpastatin domain 1 (CP1B). The mechanism of in-
hibition of this peptide and its binding site on calpain are
unknown, but it has been shown that N-terminal or C-ter-
minal truncation by a few residues reduces its inhibitory
398 S. Gil-Parrado et al.
Fig. 2 Inhibition of Calpain Activity and Calpain-Mediated
Apoptosis in Living LCLC 103H Cells by Penetratin-Linked Cal-
pastatin Exon 1B-Derived Peptide (PCP1B).
Inhibition of ionomycin-induced Suc-LLVY-amc hydrolyzing ac-
tivity. Residual ionomycin-induced Suc-LLVY-amc hydrolyzing
activity (%) measured in cells after 30 min of incubation with the
fluorogenic substrate (37°C) following pre-incubation with CP1B
or PCP1B at the indicated concentrations. 100% represents the
Suc-LLVY-amc hydrolyzing activity induced by addition of 2 µM
ionomycin in the absence of inhibitors. All experiments were per-
formed in triplicate; SD are indicated by bars; all depicted data
are significantly different (p<0.01) from the controls (0, iono-
mycin-treated cells in the absence of inhibitors).
Fig. 3 Inhibition of Ionomycin-Induced Apoptosis by Free and
Penetratin-Linked CP1B. 
To cells treated with the indicated inhibitors, annexin V-fluores-
cein and propidium iodide were added before counting and sort-
ing by FACS as described in Materials and Methods. Phos-
phatidylserine externalization (%) represents the percentage of
cells positive for phosphatidylserine externalization and nega-
tive for propidium iodide uptake after addition of 2 µM ionomycin
for 3 h at 37°C, related to the total amount of cells. All experi-
ments were performed in triplicate; SD are indicated by bars; all
depicted data are significantly different (p<0.01) from the con-
trols (0, ionomycin-treated cells in the absence of inhibitors).
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potency drastically (Uemori et al., 1990). A similar syn-
thetic 24-mer peptide, derived from a consensus se-
quence of all four inhibitory domains of porcine calpas-
tatin has been described (Croall and McGrody, 1994).
Maki et al., who introduced CP1B (Maki et al., 1989), re-
ported that it does not inhibit either papain or trypsin.
Here we confirmed and extended these findings by quan-
titative data on the inhibition of selected intracellular pro-
teases. Although only few typical cellular proteases were
considered, our data suggest that CP1B is a potent and
highly selective calpain inhibitor.
As shown previously (Kawasaki et al., 1989), inhibition
of calpain by CP1B is reversible and competitive with
substrates. Considering a Ki value of 0.2 nM as deter-
mined in this work, an intracellular concentration of about
20 nM CP1B would be required for 99% inhibition of µ-
calpain. However, even 100 µM CP1B in the surrounding
medium was not sufficient to completely inhibit calpain
activity in living cells. This discrepancy is obviously due
to the poor cell permeability of CP1B that has been ob-
served in previous cell culture studies (see references cit-
ed in ‘Introduction’) and apparently precludes this selec-
tive calpain inhibitor from use in isolated organ perfusion
and animal models as well as from potential therapeutic
application.
The most promising approach to increase cell perme-
ability of a large hydrophilic peptide like CP1B seemed to
conjugate it with a cell-penetrating peptide vector (re-
viewed in Lindgren et al., 2000b; Fischer et al., 2001). We
decided in favor of penetratin, a 16-mer peptide derived
from the third helix of the homeodomain of the Antenna-
pedia protein (Derossi et al., 1998). This peptide pene-
trates membranes through an energy-independent
mechanism that is not precisely known and translocates
conjugated cargo peptides or even proteins into the cy-
toplasm and the cell nucleus. Recently, we have used the
C-terminal heptapeptide segment of penetratin as a vec-
tor for intracellular delivery of an epoxysuccinyl peptide-
derived selective cathepsin B inhibitor (Schaschke et al.,
2002). Here, as in most previously reported applications
of penetratin, we disulfide-linked full-length Cys-pene-
tratin to Cys-CP1B. The disulfide-linked cargo is sup-
posed to be rapidly released in the reductive intracellular
milieu (Hällbrink et al., 2001).
It has been shown recently by fluorescence correlation
spectroscopy that penetratin-conjugated fluorophores
are imported into living cells even at nanomolar concen-
trations (Waizenegger et al., 2002). By fluorescence mi-
croscopy we detected uptake of biotinylated penetratin
into LCLC 103H cells at concentrations above 100 nM
(data not shown). Accordingly, our penetratin-CP1B con-
jugate effected complete inhibition of ionomycin-induced
intracellular calpain activity at concentrations in the
nanomolar range (see Figure 2), close to the concentra-
tion required for complete inhibition of isolated µ-calpain
in vitro (see above). The high selectivity for calpain over
the cathepsins L and B, caspase 3 and the 20S protea-
some remained essentially unchanged after conjugation
with penetratin (see Table 1). Therefore, PCP1B should
allow effective and selective calpain inhibition in cell cul-
ture models, isolated organs or whole animals at concen-
trations in the submicromolar or low micromolar range.
Surprisingly, the protective effect of PCP1B on cal-
pain-induced apoptosis of LCLC 103H cells (Figure 3)
was much less pronounced than was expected from inhi-
bition of intracellular calpain activity (Figure 2). On the ba-
sis of available data we cannot satisfactorily explain this
discrepance. However, phosphatidyl serine (PS) exter-
nalization, the mechanism of which is not fully under-
stood (Naito et al., 1997), is a complex process at the end
of the intrinsic apoptotic pathway triggered by calpain
(Gil-Parrado et al., 2002) and may not strictly correlate
with intracellular calpain activity determined by cleavage
of a cell-permeable peptide substrate. More than 25% of
ionomycin-induced PS externalization were inhibited nei-
ther by 10 µM PCB1B nor by 50 µM CP1B and seem to be
not calpain-dependent (Figure 3). This portion should in-
clude cells that become apoptotic in the absence of ion-
omycin (up to 35% in previous studies; see Figure 3A in
Gil-Parrado et al., 2002).
A related approach using a different cell-penetrating
peptide, the signal sequence of Kaposi’s fibroblast
growth factor (residues 7 – 22), peptide bond-linked to
the consensus sequence of the four inhibitory domains of
porcine calpastatin, has previously been reported for cal-
pain inhibition in platelets (Croce et al., 1999). This conju-
gate, called ‘calpastat’, displayed an IC50 of 70 nM for in-
hibition of isolated µ-calpain, and IC50 values between 20
and 50 µM for biological effects in platelets. The use of a
consensus sequence (Croall and McGrody, 1994) instead
of CP1B seems to be responsible for the 350-fold lower
inhibitory potency of ‘calpastat’ when compared to
PCP1B, but biological effects have been reported with
similar concentrations (Croce et al., 1999).
Due to the lack of selective calpain inhibitors that are
readily cell-permeant, even very recent studies address-
ing the physio(patho)logical relevance of calpain have
been performed using inhibitors of low selectivity or poor
cell permeability (e.g. Bordone and Campbell, 2002; Rut-
ledge and Whiteheart, 2002; Chen et al., 2002, among
many others). The new selective and cell-permeable in-
hibitor described here may help to confirm or question re-
sults obtained with less specific inhibitors and to discrim-
inate between the effects of calpain and other cellular
proteases (Yamashima, 2000). The inherent drawback of
a rather complicated synthesis of this long peptide should
be accepted as long as equally cell-permeable and spe-
cific calpain inhibitors of smaller size are not available. 
Materials and Methods
Materials 
µ-Calpain was isolated from human erythrocytes (Gabrijelcic-
Geiger et al., 2001). Human 20S proteasome was obtained from
Affiniti Research Products (Mamhead, Exeter, UK). Cathepsins L
Cell-Permeable Calpastatin Peptide 399
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and B, active recombinant caspase 3, the scrambled calpastatin
peptide and calpain inhibitor I (Ac-LLNal) were purchased from
Calbiochem (Bad Soden, Germany). Calpastatin peptide (CP1B)
was from Sigma or Calbiochem. Substrates Suc-LY-amc, Suc-
LLVY-amc, Z-FR-amc and Ac-DEVD-amc were from Bachem
(Heidelberg, Germany), ionomycin from Calbiochem, avidin-
FITC from Zymed Laboratories (South San Francisco, CA, USA).
All other reagents were of the highest purity commercially avail-
able. The LCLC 103H cell line (ACC 384) was supplied by
DSMZ-GmbH (Braunschweig, Germany).
Peptide Synthesis and Purification
Compound 1 (Figure 1), calpastatin exon 1B peptide functional-
ized at its N-terminus with a S-Npys-activated N-acetylated cys-
teine residue, was initially custom synthesized by the Micro-
chemical Facility of Emory University, Winship Cancer Center
(Atlanta, GA, USA) and later synthesized in our laboratory by the
method described below for Compound 2. Compound 2 (Fig-
ure 1), penetratin N-terminally elongated with a N-acetylated
cysteine residue, was synthesized on a Applied Biosystems
peptide synthesizer (model 431A) by standard Fmoc/tBu chem-
istry on Rink amide (MBHA) resin using double coupling of
Fmoc-amino acids/HBTU/HOBt/DIEA (1:1:1:2; 4 equiv.). N-ter-
minal acetylation was carried out with acetic anhydride/DIEA
(1:1.5; 10 equiv.) and final cleavage/deprotection was performed
with 95% aq TFA/triisopropylsilane (98.5:1.5) yielding StBu-pro-
tected 2 which was purified by RP-HPLC on Nucleosil C18 using
a linear gradient form 18% B to 45% B within 60 min (eluent A:
0.1% aq TFA; eluent B: 0.08% TFA in acetonitrile). The resulting
product was deprotected by treatment with tri-n-butylphos-
phine (5 equiv.) in 95% aq TFE. Conjugate 3 was synthesized by
adding under an argon atmosphere peptide 2 (1 equiv.) dis-
solved in 50 mM NH4OAc-buffer (pH 5, degassed and saturated
with argon) slowly to a solution of 1 (1 equiv.) in the same buffer.
After purification by gel chromatography on Fractogel HW 40 S
using 1% aq AcOH as eluent, 3 was fully characterized by RP-
HPLC, quantitative amino acid analysis, and ESI-MS.
Inhibition Assays and Ki Determination
Inhibition of µ-calpain (0.5 – 1 nM) was measured at 12°C (to slow
down inactivation by autolysis) with the fluorogenic substrate
Suc-LY-amc (250 µM) in 50 mM Tris/HCl, pH 7.5, 100 mM NaCl,
0.015% Brij-35 (calpain buffer), 150 – 200 µM CaCl2, 1 mM dithio-
threitol (DTT). Cathepsin L (0.25 nM) was assayed at 25°C,
pH 5.5 with 25 µM Suc-LY-amc and cathepsin B (25 pM) at 30°C
with Z-FR-amc (10 µM) in 0.25 mM sodium acetate, pH 5.5, 2 mM
EDTA, 0.015% Brij-35. The chymotryptic activity of the human
20S proteasome (2 nM) was measured at 30°C with Suc-LLVY-
amc (10 µM) in 50 mM Tris/HCl, pH 7.5, 100 mM NaCl, 0.5 mM
EDTA, 0.025% SDS and caspase 3 activity at 25°C with Ac-
DEVD-amc (5 µM) in 50 mM HEPES, pH 7.2, 100 mM NaCl, 1 mM
EDTA, 10% sucrose, 0.1% CHAPS and 10 mM DTT. Continuous
assays were performed recording fluorescence (excitation
380 nm, emission 460 nm) essentially as described in Machleidt
et al. (1993). After preactivation of the enzymes with DTT (exept
the proteasome) in the presence of substrate and of CaCl2 (µ-
calpain), about 5 – 10 different inhibitor concentrations, dis-
solved and prediluted in calpain buffer (or DMSO for AcLLNal),
were added (max. 1% of the total test volume), and the reaction
was followed until equilibrium. Ki values for the inhibition of µ-
calpain by the free and the penetratin-conjugated calpastatin
peptide were obtained from presteady-state kinetics, fitting the
progress data by nonlinear regression analysis to the integrated
equation of Morrison (Morrison, 1982). From the rate constants
kon and koff the Ki-values were calculated as Ki = koff/kon. All other
inhibition constants were calculated from the initial and steady
state rates using the equation for classical inhibition. Ki values
were corrected for competition with the substrates. In cases of
less than 10% inhibition, the Ki-value was assumed to be at least
10-fold the highest used inhibitor concentration.
Cell Culture
For routine cell culture, RPMI 1640 medium (Gibco-BRL) was
supplemented with 10% fetal calf sera (Sigma) and 0.6% L-glu-
tamine (Gibco-BRL). Cells were maintained at 37°C in a humidi-
fied 5% CO2 atmosphere. For inhibition experiments, the cells
were maintained in serum-free HEPES-RPMI 1640 (Gibco-BRL).
When being subcultured, cells were lifted using trypsin-EDTA
solution (Gibco-BRL).
Protease Activity and Inhibition Assay in Living Cells
Suc-LLVY-amc hydrolyzing activity was determined by measur-
ing hydrolysis of the peptidyl 7-amino bond of this fluorogenic
substrate in LCLC 103H cells, plated on 24-well plates (105
cells/well), in Hepes-buffered serum-free growth medium. Cells
were pre-incubated with Suc-LLVY-amc (160 µM) for 1 h at 37°C
in a humidified 5% CO2 incubator. Substrate hydrolysis was
monitored using a fluorescence reading system (Fluoroskan as-
cent) with filter settings of 355±20 nm for excitation and
460±20 nm for emission. Prior to addition of 2 µM ionomycin, the
basal fluorescence, F0,was recorded. Fluorescence readings, Ft,
were collected every 5 min up to 120 min at 37°C. Subsequent-
ly, plates were removed from the scanner, and incubated with ly-
sis buffer (50 mM Hepes/KOH, 150 mM NaCl, 1% NP 40, pH 7.4)
for 2 h at room temperature for protein concentration measure-
ments. As there were no statistically significant differences in
protein content between the wells, ionomycin-dependent prote-
olytic activity was expressed in arbitrary units and calculated as
the linear slope ∆F = (Ft-Fo)/(t-to).
Inhibition of ionomycin-induced Suc-LLVY-amc hydrolyzing
activity was measured after preincubation of the cells for 1 h at
37°C with the inhibitors CP1B and PCP1B dissolved in calpain
buffer and diluted in Hepes-buffered serum-free growth medium
at the indicated concentrations (see Figure 2) before addition of
substrate. Note that these inhibitor concentrations were chosen
taking into account prior results (Gil-Parrado et al., 2002) and the
maintenance of cell viability. The residual activity (%) was ex-
pressed as [(∆F - ∆Finh)/ ∆F] × 100, where ∆Finh is the ionomycin-
induced activity in the presence of inhibitor. Triplicate measure-
ments were performed for each sample.
FACS Analysis of Apoptotic Cells
Cells were treated with 2 µM ionomycin for 3 h at 37°C. Before
being counted and sorted by FACS, annexin V-fluorescein and
propidium iodide were added as described (Gil-Parrado et al.,
2002). Phosphatidylserine externalization (%) represents the
percentage of cells positive for phosphatidylserine externaliza-
tion and negative for propidium iodide uptake, related to the to-
tal amount of cells. Inhibition of phosphatidylserine externaliza-
tion was measured after pre-incubation of the cells for 1 h with
different concentrations of the inhibitors CP1B and PCP1B, fol-
lowed by incubation with ionomycin and FACS counting. All ex-
periments were performed in triplicate.
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